Benchmarks
The growth of tumors depends on the formation and maintenance of a vascular supply. In response to low oxygen conditions within the tumor microenvironment, tumor cells stimulate the process of tumor vascularization through the secretion of proangiogenic factors (1) . This principle has led to the development of anti-cancer therapies that inhibit tumor angiogenesis (2) . However, much still needs to be learned about the biological process of tumor angiogenesis and how best to inhibit it to provide the greatest therapeutic effect.
A number of vascular imaging probes have been developed that allow for the noninvasive detection of blood vessels in live animals and embryos using fluorescent imaging. Current vascular imaging probes include fluorescently labeled macromolecules (3, 4) , liposomes (5), nanoparticles (6, 7) , and quantum dots (8) . There are specific advantages and disadvantages related to cost, toxicity, bioavailability, and stability for each of these probes. All of these agents can be categorized as "blood-pooling probes," whereby they cannot permeate intact vasculature, thus providing the specificity required for vascular imaging. However, these vascular probes have a significant disadvantage for use in detecting the vascularization of tumors.
Unlike the hierarchically organized vasculature of normal tissue, tumors form highly irregular and often immature blood vessels resulting in inconsistent blood flow and poor vascular integrity (9) . This hallmark of tumor vasculature causes bloodpooling vascular imaging probes to leak from tumor vasculature and selectively accumulate in solid tumors. This results in an artificially high and prolonged probe signal within tumors, independent of the density of tumor vasculature. Many probes with a long half-life show tumor-specific signal for weeks following the initial intravenous injection (10, 11) . This suggests that the high intratumoral signal detected with blood-pooling vascular imaging probes is, at least in part, an artifact of vessel leakiness and a lack of probe clearance from within tumors. Reports have shown that if imaging of intravascular probes is done acutely following intravenous injection (≤30 min), minimal leakage will occur (12) , which provides suitable vascular contrast and specificity for initial imaging. However, subsequent imaging can only be carried out after the tumor's complete clearance of previous probe injections. This property of blood-pooling probes makes them unsuitable for monitoring dynamic changes in the tumor vasculature of animal models during tumor growth as well as in response to antiangiogenic therapy.
Here we describe a technique to detect and monitor dynamic changes in the tumor vasculature of living animals without the use of vascular imaging probes. Using commercially available multispectral imaging technology, we were able to simultaneously image a range of wavelengths. This multiplexing capability allows differentiation and unmixing of spectral differences as small as 10 nm from a single image. Using this technology, we have detected and quantified a distinct spectral emission signature of blood vessels present in fluorescent tumors.
One million HCT116 p53-null colon carcinoma cells with stable expression of DsRed protein (RFP) (Clontech, Mountainview, CA, USA) were mixed 1:1 with 50% Matrigel Matrix (BD Biosciences, San Jose, CA, USA) and injected subcutaneously into the rear flanks of nude mice (The Jackson Laboratory, Bar Harbor, ME, USA). After three weeks, tumors were 1-2 cm. Mice were anesthetized with ketamine/xylazine and imaged using either the Maestro in vivo fluorescent imager with a Xenon light source (CRi, Inc., Woburn, MA, USA) or the Nuance camera (CRi, Inc.) attached to an AZ100 fluorescence dissecting microscope with a mercury light source (Nikon, Melville, NY, USA).
The manufacturers CRi and Nikon recommended filter sets for imaging RFP with the Maestro and Nuance/ AZ100 setup, respectively. 530/50 nm excitation and 580 nm longpass filters were used for the Maestro, and 470/40 nm excitation and 495 nm longpass filters were used for the Nuance/AZ100 setup. The multispectral acquisition range was 580-800 nm in 10-nm steps. Following image acquisition we used the spectral processing feature of the CRi software to mark an area of the tumor where a large blood vessel was visualized by the naked eye and saved the spectral emission signature as a red pseudocolor in our spectral library ( Figure 1A) . We then marked an area of the tumor where no blood vessel was visually apparent and saved the spectral emission signature as a green pseudocolor in our spectral library ( Figure  1A ). The spectral emission signatures of the two areas were nearly identical except that the vascular signature (red Benchmarks pseudocolor) exhibited a 10-nm upward shift in wavelength. The saved spectral signatures were then unmixed and mapped across the bitmap of acquired tumor images. We presume the increase in wavelength corresponds to either a decrease in the frequency, or the scattering of fluorescent light emitted from tumor cells as it passes through blood vessels present within the tumor. Therefore, fluorescent light is derived from the tumor cells but altered by the presence of blood vessels between the tumor cells and the detection source.
With multispectral unmixing we identified blood vessels present throughout tumor images taken at 1× magnification using the Nuance/ AZ100 setup ( Figure 1B ). At increased (8.7×) magnification we observed capillaries of approximately 10 μm in diameter growing throughout the tumor ( Figure 1C ), illustrating the sensitivity of this method of vascular imaging. Depth penetration of multispectral vascular imaging is determined by the wavelength as well as the brightness of the endogenous fluorophore being expressed within the tumor cells. We also observed a decrease in the depth penetration of vascular imaging as the magnification was increased. Therefore, the deeper the blood vessel is located, the bigger it must be to be 
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detected by the multispectral vascular imaging technique. Tumor vascularization was also detected via wholebody imaging in mice using the CRi Maestro ( Figure 1D, left panel) . An enlarged tumor image shows that both large and small vessels can also be detected macroscopically ( Figure  1D , right panel). Unmixed spectral signatures can then be independently quantified to calculate a vascular index for each tumor ( Figure 1E ). In this way, tumor vascularization can be quantitatively measured and normalized for tumor size, which provides the ability to measure changes in tumor vascularization over time.
We next compared the sensitivity of multispectral unmixing to other commercially available vascular imaging probes. A mouse was given an intravenous (i.v.) injection of Angiosense 680 nm (Visen, Woburn, MA, USA) (100 μL, 13 μM in PBS) 1 h prior to anesthesia, as well as an injection of Q-tracker 800 nm (Invitrogen, Carlsbad, CA, USA) (100 μL, 0.6 μM in PBS) 30 min prior to anesthesia. The mouse was imaged using the Nuance/AZ100 setup. First, the RFP signal was imaged using the 470/40 nm excitation and 495 nm longpass filters with a multispectral acquisition range of 580-800 nm ( Figure 2A) . Next, the Angiosense 680 nm probe was imaged using a 665/45 nm excitation and 695 nm longpass filters with an acquisition range of 680-950 nm ( Figure 2B) . Finally, the Q-tracker 800 nm probe was imaged using the 710/75 nm excitation and 750 nm longpass filters with an acquisition range of 680-950 nm ( Figure 2C ). The three images show the distinct emission spectra of the multispectral unmixing technique as well as the two vascular imaging probes. Each method detected the same tumor blood vessels, which demonstrates comparable sensitivity of the multispectral unmixing method and the two commercially available vascular imaging probes.
We then performed a proof-ofprinciple antiangiogenic therapy trial in mice with HCT116 p53-null, RFP-expressing tumors. Two weeks after tumor implantation, mice were treated with either a saline control or bevacizumab (10mg/kg), dosed intravenously every other day for one week. Tumor vascularization was monitored in real-time with the Maestro small- 
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BioSpec Products animal imager, performing both multispectral imaging as well as imaging with the Angiosense 750 nm fluorescent probe. With real-time multispectral vascular imaging we detected an average relative decrease in the vascular indices of three tumors treated with bevacizumab as compared with an average relative increase in the vascular indices of three control-treated tumors ( Figure 3A) . With real-time imaging using Angiosense 750 nm, we detected an average relative increase in both control-and bevacizumab-treated tumors, although the increase was slightly less in bevacizumab-treated tumors on day 6 of therapy ( Figure 3B ). Angiosense 750 nm was imaged 20 min after retro-orbital injection.
Representative images of tumors imaged via multispectral vascular imaging before and after therapy are shown in Figure 3C . Following the bevacizumab treatment trial, the tumors were fixed in 4% paraformaldehyde, paraffin-embedded and sectioned for immunohistochemistry. Tumor sections were stained with CD34 (MEC 14.7) (Abcam, Cambridge, MA, USA) diluted 1:50 in PBT (PBS, 0.1% BSA, 0.2% Triton X-100). Quantification of CD34-positive blood vessels showed a significant decrease in the average number of blood vessels per 2.5× field of view in bevacizumab-treated tumors as compared with control-treated tumors (P < 0.001, n = 9, Student's t-test) ( Figure 3D ). Figure 3E shows representative fields from the control-treated tumor with the greatest relative vascular index increase and the bevacizumab-treated tumor with the greatest relative vascular index decrease as measured by in vivo multispectral vascular imaging. This preclinical animal trial demonstrates that in vivo vascular imaging using multispectral unmixing is able to reliably detect subtle changes in tumor vascularization in real time, acutely following antiangiogenic therapy.
In this report we have demonstrated a novel method by which tumor vascularization can be imaged noninvasively in fluorescent tumors without the use of exogenously administered vascular imaging probes. By obviating the need for vascular probes, common problems associated with their use-including high cost, toxicity, inconsistent delivery and differential bioavailability among animals-are eliminated. Furthermore, this method completely eliminates the problem associated with blood-pooling probes of high tumor accumulation resulting from vessel leakiness. Therefore, we believe that the multispectral unmixing method described here is superior to currently used vascular imaging probes for detecting tumor vascularization as well as for monitoring dynamic changes in tumor vascularization. Maestro systems are now available with Dynamic Contrast Enhancement (DyCE™), the powerful tool for generating alloptical anatomic maps from the same animal and dramatically reducing the time it takes to separate specific from non-specific binding.
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